Review



anti lyp ig  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems anti lyp ig
    Anti Lyp Ig, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti lyp ig/product/R&D Systems
    Average 93 stars, based on 20 article reviews
    anti lyp ig - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    93
    R&D Systems anti lyp ig
    Anti Lyp Ig, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti lyp ig/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti lyp ig - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    93
    R&D Systems goat anti human ptpn22 polyclonal antibody
    <t>PTPN22</t> Ser 325 is an inducible GSK3 phosphorylation site in human T cells. A , schematic illustration of 3× FLAG PTPN22 protein purification ( left panel ) and mass spectra ( right panel ) indicating Ser 325 phosphorylation in immunoprecipitated PTPN22 from 3× FLAG PTPN22 Jurkat WT cells cross-linked with antibodies against human CD3/CD28. Data is representative of three independent biological replicates. Peptide MS2 fragmentation pattern shown displaying m/z and peptide spectral match intensity. B , Western blot analysis obtained using a phospho-Ser 325 –specific antibody in immunoprecipitated PTPN22 from the lysates of PTPN22 KO Jurkat cells overexpressing 3× FLAG WT or S325A PTPN22 and treated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗ p < 0.05. C , endogenous Ser 325 phosphorylation was analyzed by Western blotting in PTPN22 immunoprecipitated from lysates of 3× FLAG WT PTPN22 Jurkat cells stimulated with antibodies against human CD3/CD28 for the indicated times ( left panel ). Quantifications of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the Kruskal–Wallis test, ∗ p < 0.05. D , immunoprecipitation analysis of endogenous PTPN22 Ser 325 phosphorylation in lysates of human primary CD4 + effector T cells stimulated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in five independent experiments ( right panel ). Statistical significance was assessed by using the Kolmogorov–Smirnov test, ∗∗ p < 0.01. E , prediction of potential kinases responsible for PTPN22 Ser 325 phosphorylation in descending order from left to right . F , immunoprecipitation analysis of phospho-PTPN22 Ser 325 in lysates of 3× FLAG PTPN22 WT Jurkat cells with or without incubation with 5 μM GSK3 inhibitor IX and stimulation with antibodies against human CD3/CD28 ( left panel ). Quantifications of phospho-Ser 325 /total PTPN22 ratio from Western blot analysis of four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. G , immunoprecipitation analysis of PTPN22 and GSK3 interaction in lysates of BioID2 Jurkat cells ( left panel ). Histograms shows quantifications of immunoprecipitated GSK3 α/β based on the Western blot analysis and are representative of four independent experiments ( right panel ). Statistical significance was assessed using the Kolmogorov–Smirnov test, ∗ p < 0.05. CD, cluster of differentiation; GSK3, glycogen synthase kinase 3; PTPN22, protein tyrosine phosphatase nonreceptor type 22.
    Goat Anti Human Ptpn22 Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti human ptpn22 polyclonal antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    goat anti human ptpn22 polyclonal antibody - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    94
    R&D Systems goat anti human ptpn22
    Figure 1. The Src homology 3 (SH3) domain of UBASH3A interacts with <t>PTPN22</t> in Jurkat cells. (a) Lysates from Jurkat cells and GM12155 cells were immunoprecipitated with anti-UBASH3A or IgG. The immunoprecipitates and the input lysates were subjected to immunoblotting with anti-PTPN22, and subsequently, with anti-UBASH3A after stripping. The asterisk indicates the monoubiquitinated form of UBASH3A. The vertical white line indicates that the lanes are not consecutive, although they are of the same gel. Note that the 91 kDa band observed in lane 4 (upper panel) is likely a false positive result because UBASH3A is not detected in GM12155 cells (bottom panel). (b) Glutathione S-transferase (GST) pull-down assay using GST or GST-tagged ubiquitin-associated (UBA), SH3, and phosphoglycerate mutase-like (PGM) domains of UBASH3A with lysate from Jurkat cells. The pull-down products and the Jurkat lysate were subjected to immunoblotting with anti-PTPN22.
    Goat Anti Human Ptpn22, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti human ptpn22/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    goat anti human ptpn22 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    93
    R&D Systems antibodies goat anti human ptpn22 lyp
    H21I substitution in the SH3 domain of Csk selectively disrupts self-association. ( a ) Position of the SH3 domain in full-length Csk (PDB ID: 1K9A ). ( b ) Csk residue H21 in the SH3/SH3 homodimer interface (PDB ID 1CSK ). The position of <t>PTPN22</t> peptide binding to the SH3 domain was derived in PyMol using PDB IDs 1K9A 1CSK , 1JEG , 1QWE , and 2P6X . ( c ) Representative immunoblots of whole-cell or Myc-immunodepleted lysates from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both H21I). ( d ) Corresponding immunoblots of transfected Csk and endogenous PTPN22 in Myc immunoprecipitates. ( e ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: standard error of the mean (SEM), n = 4 independent experiments. Significance: one-way ANOVA with Tukey’s multiple comparison test (Sig.ANOVA) ****p < 0.0001, ***p = 0.0001 or 0.0008.
    Antibodies Goat Anti Human Ptpn22 Lyp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies goat anti human ptpn22 lyp/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    antibodies goat anti human ptpn22 lyp - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    90
    R&D Systems the anti-lyp goat polyclonal ab
    H21I substitution in the SH3 domain of Csk selectively disrupts self-association. ( a ) Position of the SH3 domain in full-length Csk (PDB ID: 1K9A ). ( b ) Csk residue H21 in the SH3/SH3 homodimer interface (PDB ID 1CSK ). The position of <t>PTPN22</t> peptide binding to the SH3 domain was derived in PyMol using PDB IDs 1K9A 1CSK , 1JEG , 1QWE , and 2P6X . ( c ) Representative immunoblots of whole-cell or Myc-immunodepleted lysates from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both H21I). ( d ) Corresponding immunoblots of transfected Csk and endogenous PTPN22 in Myc immunoprecipitates. ( e ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: standard error of the mean (SEM), n = 4 independent experiments. Significance: one-way ANOVA with Tukey’s multiple comparison test (Sig.ANOVA) ****p < 0.0001, ***p = 0.0001 or 0.0008.
    The Anti Lyp Goat Polyclonal Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/the anti-lyp goat polyclonal ab/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    the anti-lyp goat polyclonal ab - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    94
    R&D Systems ptpn22
    H21I substitution in the SH3 domain of Csk selectively disrupts self-association. ( a ) Position of the SH3 domain in full-length Csk (PDB ID: 1K9A ). ( b ) Csk residue H21 in the SH3/SH3 homodimer interface (PDB ID 1CSK ). The position of <t>PTPN22</t> peptide binding to the SH3 domain was derived in PyMol using PDB IDs 1K9A 1CSK , 1JEG , 1QWE , and 2P6X . ( c ) Representative immunoblots of whole-cell or Myc-immunodepleted lysates from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both H21I). ( d ) Corresponding immunoblots of transfected Csk and endogenous PTPN22 in Myc immunoprecipitates. ( e ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: standard error of the mean (SEM), n = 4 independent experiments. Significance: one-way ANOVA with Tukey’s multiple comparison test (Sig.ANOVA) ****p < 0.0001, ***p = 0.0001 or 0.0008.
    Ptpn22, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ptpn22/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    ptpn22 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    Image Search Results


    PTPN22 Ser 325 is an inducible GSK3 phosphorylation site in human T cells. A , schematic illustration of 3× FLAG PTPN22 protein purification ( left panel ) and mass spectra ( right panel ) indicating Ser 325 phosphorylation in immunoprecipitated PTPN22 from 3× FLAG PTPN22 Jurkat WT cells cross-linked with antibodies against human CD3/CD28. Data is representative of three independent biological replicates. Peptide MS2 fragmentation pattern shown displaying m/z and peptide spectral match intensity. B , Western blot analysis obtained using a phospho-Ser 325 –specific antibody in immunoprecipitated PTPN22 from the lysates of PTPN22 KO Jurkat cells overexpressing 3× FLAG WT or S325A PTPN22 and treated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗ p < 0.05. C , endogenous Ser 325 phosphorylation was analyzed by Western blotting in PTPN22 immunoprecipitated from lysates of 3× FLAG WT PTPN22 Jurkat cells stimulated with antibodies against human CD3/CD28 for the indicated times ( left panel ). Quantifications of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the Kruskal–Wallis test, ∗ p < 0.05. D , immunoprecipitation analysis of endogenous PTPN22 Ser 325 phosphorylation in lysates of human primary CD4 + effector T cells stimulated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in five independent experiments ( right panel ). Statistical significance was assessed by using the Kolmogorov–Smirnov test, ∗∗ p < 0.01. E , prediction of potential kinases responsible for PTPN22 Ser 325 phosphorylation in descending order from left to right . F , immunoprecipitation analysis of phospho-PTPN22 Ser 325 in lysates of 3× FLAG PTPN22 WT Jurkat cells with or without incubation with 5 μM GSK3 inhibitor IX and stimulation with antibodies against human CD3/CD28 ( left panel ). Quantifications of phospho-Ser 325 /total PTPN22 ratio from Western blot analysis of four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. G , immunoprecipitation analysis of PTPN22 and GSK3 interaction in lysates of BioID2 Jurkat cells ( left panel ). Histograms shows quantifications of immunoprecipitated GSK3 α/β based on the Western blot analysis and are representative of four independent experiments ( right panel ). Statistical significance was assessed using the Kolmogorov–Smirnov test, ∗ p < 0.05. CD, cluster of differentiation; GSK3, glycogen synthase kinase 3; PTPN22, protein tyrosine phosphatase nonreceptor type 22.

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: PTPN22 Ser 325 is an inducible GSK3 phosphorylation site in human T cells. A , schematic illustration of 3× FLAG PTPN22 protein purification ( left panel ) and mass spectra ( right panel ) indicating Ser 325 phosphorylation in immunoprecipitated PTPN22 from 3× FLAG PTPN22 Jurkat WT cells cross-linked with antibodies against human CD3/CD28. Data is representative of three independent biological replicates. Peptide MS2 fragmentation pattern shown displaying m/z and peptide spectral match intensity. B , Western blot analysis obtained using a phospho-Ser 325 –specific antibody in immunoprecipitated PTPN22 from the lysates of PTPN22 KO Jurkat cells overexpressing 3× FLAG WT or S325A PTPN22 and treated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗ p < 0.05. C , endogenous Ser 325 phosphorylation was analyzed by Western blotting in PTPN22 immunoprecipitated from lysates of 3× FLAG WT PTPN22 Jurkat cells stimulated with antibodies against human CD3/CD28 for the indicated times ( left panel ). Quantifications of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in four independent experiments ( right panel ). Statistical significance was assessed using the Kruskal–Wallis test, ∗ p < 0.05. D , immunoprecipitation analysis of endogenous PTPN22 Ser 325 phosphorylation in lysates of human primary CD4 + effector T cells stimulated with antibodies against human CD3/CD28 for the indicated time ( left panel ). Quantification of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated conditions in five independent experiments ( right panel ). Statistical significance was assessed by using the Kolmogorov–Smirnov test, ∗∗ p < 0.01. E , prediction of potential kinases responsible for PTPN22 Ser 325 phosphorylation in descending order from left to right . F , immunoprecipitation analysis of phospho-PTPN22 Ser 325 in lysates of 3× FLAG PTPN22 WT Jurkat cells with or without incubation with 5 μM GSK3 inhibitor IX and stimulation with antibodies against human CD3/CD28 ( left panel ). Quantifications of phospho-Ser 325 /total PTPN22 ratio from Western blot analysis of four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA test followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. G , immunoprecipitation analysis of PTPN22 and GSK3 interaction in lysates of BioID2 Jurkat cells ( left panel ). Histograms shows quantifications of immunoprecipitated GSK3 α/β based on the Western blot analysis and are representative of four independent experiments ( right panel ). Statistical significance was assessed using the Kolmogorov–Smirnov test, ∗ p < 0.05. CD, cluster of differentiation; GSK3, glycogen synthase kinase 3; PTPN22, protein tyrosine phosphatase nonreceptor type 22.

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: Protein Purification, Immunoprecipitation, Western Blot, Incubation

    Phosphorylation of PTPN22 Ser 325 enhances the inhibitory effect of PTPN22 on T cell receptor signaling. A , immunoprecipitation analysis of PTPN22 Ser 325 phosphorylation in lysates of 3× FLAG PTPN22 WT and CRISPR/Cas9-mediated S325A KI Jurkat cells stimulated with antibodies against human CD3/CD28 for the indicated time by Western blotting ( left panel ). Histogram shows quantifications of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated condition and is representative of four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. B , dual-luciferase reporter assay analysis of full-length PTPN22 inhibition of TCR signaling in PTPN22 KO Jurkat cells overexpressing full-length 3× FLAG WT, S325E, or S325A PTPN22 together with NFAT/AP-1 firefly and Renilla luciferase reporters and stimulated with antibodies against human CD3/CD28. Luciferase activity was measured ( left panel ), and the numbers on the y -axis indicate NFAT/AP-1 firefly luciferase activity normalized first to Renilla luciferase activity in each group (KO, WT, or S325 mutant), then to the amount of PTPN22 relative to that of GAPDH as assessed by Western blotting ( right panel ). Mean ± SEM are shown from three independent experiments each with three replicates per condition. Statistical significance was assessed by using the Kruskal–Wallis test, ∗ p < 0.05. C and D , Western blot analysis of TCR signaling in 3× FLAG PTPN22 WT, and CRISPR/Cas9 mediated S325A ( C ) or S325E ( D ) KI Jurkat cells treated with antibodies against human CD3/CD28 for indicated time, followed by detection of phosphorylated LCK (Tyr 394 ), ZAP70 (Tyr 3 19 ), and PLC-γ (Tyr 783 ) in lysates ( left panels ). Histograms show quantification of phosphorylated LCK, ZAP70, and PLC-γ normalized to relative total protein by four independent experiments ( right panels ). Statistical significance was assessed using the Kolmogorov–Smirnov test, ∗ p < 0.05. E and F , flow cytometry analysis of TCR-induced CD69 expression in 3× FLAG PTPN22 WT, S325A ( E ), or S325E ( F ) KI Jurkat cells treated with (stimulated) or without (mock) antibodies against human CD3/CD28 for 4 h. Histograms show median fluorescent intensity (MFI) from seven independent experiments. Statistical significance was assessed using two-way ANOVA, followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. AP-1, activator protein-1; CD, cluster of differentiation; GSK3, glycogen synthase kinase 3; LCK, lymphocyte-specific protein tyrosine kinase; NFAT, nuclear factor of activated T cells; PLC, phospholipase C; PTPN22, protein tyrosine phosphatase nonreceptor type 22; TCR, T cell receptor; ZAP70, zeta-chain–associated protein kinase 70.

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: Phosphorylation of PTPN22 Ser 325 enhances the inhibitory effect of PTPN22 on T cell receptor signaling. A , immunoprecipitation analysis of PTPN22 Ser 325 phosphorylation in lysates of 3× FLAG PTPN22 WT and CRISPR/Cas9-mediated S325A KI Jurkat cells stimulated with antibodies against human CD3/CD28 for the indicated time by Western blotting ( left panel ). Histogram shows quantifications of the phospho-Ser 325 /total PTPN22 ratio normalized to nonstimulated condition and is representative of four independent experiments ( right panel ). Statistical significance was assessed using the two-way ANOVA followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. B , dual-luciferase reporter assay analysis of full-length PTPN22 inhibition of TCR signaling in PTPN22 KO Jurkat cells overexpressing full-length 3× FLAG WT, S325E, or S325A PTPN22 together with NFAT/AP-1 firefly and Renilla luciferase reporters and stimulated with antibodies against human CD3/CD28. Luciferase activity was measured ( left panel ), and the numbers on the y -axis indicate NFAT/AP-1 firefly luciferase activity normalized first to Renilla luciferase activity in each group (KO, WT, or S325 mutant), then to the amount of PTPN22 relative to that of GAPDH as assessed by Western blotting ( right panel ). Mean ± SEM are shown from three independent experiments each with three replicates per condition. Statistical significance was assessed by using the Kruskal–Wallis test, ∗ p < 0.05. C and D , Western blot analysis of TCR signaling in 3× FLAG PTPN22 WT, and CRISPR/Cas9 mediated S325A ( C ) or S325E ( D ) KI Jurkat cells treated with antibodies against human CD3/CD28 for indicated time, followed by detection of phosphorylated LCK (Tyr 394 ), ZAP70 (Tyr 3 19 ), and PLC-γ (Tyr 783 ) in lysates ( left panels ). Histograms show quantification of phosphorylated LCK, ZAP70, and PLC-γ normalized to relative total protein by four independent experiments ( right panels ). Statistical significance was assessed using the Kolmogorov–Smirnov test, ∗ p < 0.05. E and F , flow cytometry analysis of TCR-induced CD69 expression in 3× FLAG PTPN22 WT, S325A ( E ), or S325E ( F ) KI Jurkat cells treated with (stimulated) or without (mock) antibodies against human CD3/CD28 for 4 h. Histograms show median fluorescent intensity (MFI) from seven independent experiments. Statistical significance was assessed using two-way ANOVA, followed by Bonferroni’s post hoc test, ∗∗ p < 0.01. AP-1, activator protein-1; CD, cluster of differentiation; GSK3, glycogen synthase kinase 3; LCK, lymphocyte-specific protein tyrosine kinase; NFAT, nuclear factor of activated T cells; PLC, phospholipase C; PTPN22, protein tyrosine phosphatase nonreceptor type 22; TCR, T cell receptor; ZAP70, zeta-chain–associated protein kinase 70.

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: Immunoprecipitation, CRISPR, Western Blot, Luciferase, Reporter Assay, Inhibition, Activity Assay, Mutagenesis, Flow Cytometry, Expressing

    In vitro catalytic activity of PTPN22 and its variants. A and B , phosphatase activity assays were performed using immunoprecipitated PTPN22 from PTPN22 WT, or S325A, S325E KI Jurkat cells, and DiFMUP as a substrate. Histograms ( left panel ) show quantification of initial rates of reaction normalized to the amount of PTPN22 WT as assessed by Western blotting ( right panel ). Mean ± SEM are shown from five ( A ) and ten ( B ) independent experiments. Statistical significance was assessed by using the Kolmogorov–Smirnov test, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C and D , dual-luciferase reporter assay analysis of truncated WT and S325E inhibition of TCR signaling in PTPN22 KO Jurkat cells overexpressing 3 × FLAG PTPN22 1-340 ( C ), or PTPN22 1-330 ( D ) WT, and S325E together with NFAT/AP-1 firefly and Renilla luciferase reporters and stimulated with antibodies against human CD3/CD28. Luciferase activity was measured and quantified as described in <xref ref-type=Figure 2 B . Means ± SEM are shown from three or four independent experiments each with three replicates per condition. Statistical significance was assessed by using the Kruskal–Wallis test, ∗ p < 0.05, ∗∗ p < 0.01. E , representative SDS-PAGE of final purified samples of PTPN22 1-330 WT and S325E recombinant proteins. F and G , phosphatase activity assays were performed by using recombinant PTPN22 1-330 WT or S325E and DiFMUP as a substrate. F , representative Michaelis–Menten curve of eight independent experiments each with three technical replicates and representative SDS PAGE of 1 μM PTPN22 1-330 WT and S325E recombinant proteins. G , dot plot showing k cat and K M . Each data point represents one of eight independent experiments performed as in (F). Statistical significance was assessed using two-tailed Mann–Whitney test, ∗ p < 0.05, ∗∗ p < 0.01. AP-1, activator protein-1; CD, cluster of differentiation; DiFMUP, 6,8-difluoro-4-methylumbelliferyl phosphate; NFAT, nuclear factor of activated T cells; PTPN22, protein tyrosine phosphatase nonreceptor type 22; TCR, T cell receptor. " width="100%" height="100%">

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: In vitro catalytic activity of PTPN22 and its variants. A and B , phosphatase activity assays were performed using immunoprecipitated PTPN22 from PTPN22 WT, or S325A, S325E KI Jurkat cells, and DiFMUP as a substrate. Histograms ( left panel ) show quantification of initial rates of reaction normalized to the amount of PTPN22 WT as assessed by Western blotting ( right panel ). Mean ± SEM are shown from five ( A ) and ten ( B ) independent experiments. Statistical significance was assessed by using the Kolmogorov–Smirnov test, ∗∗ p < 0.01, ∗∗∗ p < 0.001. C and D , dual-luciferase reporter assay analysis of truncated WT and S325E inhibition of TCR signaling in PTPN22 KO Jurkat cells overexpressing 3 × FLAG PTPN22 1-340 ( C ), or PTPN22 1-330 ( D ) WT, and S325E together with NFAT/AP-1 firefly and Renilla luciferase reporters and stimulated with antibodies against human CD3/CD28. Luciferase activity was measured and quantified as described in Figure 2 B . Means ± SEM are shown from three or four independent experiments each with three replicates per condition. Statistical significance was assessed by using the Kruskal–Wallis test, ∗ p < 0.05, ∗∗ p < 0.01. E , representative SDS-PAGE of final purified samples of PTPN22 1-330 WT and S325E recombinant proteins. F and G , phosphatase activity assays were performed by using recombinant PTPN22 1-330 WT or S325E and DiFMUP as a substrate. F , representative Michaelis–Menten curve of eight independent experiments each with three technical replicates and representative SDS PAGE of 1 μM PTPN22 1-330 WT and S325E recombinant proteins. G , dot plot showing k cat and K M . Each data point represents one of eight independent experiments performed as in (F). Statistical significance was assessed using two-tailed Mann–Whitney test, ∗ p < 0.05, ∗∗ p < 0.01. AP-1, activator protein-1; CD, cluster of differentiation; DiFMUP, 6,8-difluoro-4-methylumbelliferyl phosphate; NFAT, nuclear factor of activated T cells; PTPN22, protein tyrosine phosphatase nonreceptor type 22; TCR, T cell receptor.

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: In Vitro, Activity Assay, Immunoprecipitation, Western Blot, Luciferase, Reporter Assay, Inhibition, SDS Page, Purification, Recombinant, Two Tailed Test, MANN-WHITNEY

    Effect of Ser 325 phosphorylation mimic on the deuterium exchange rates of PTPN22 1 to 330. A , rainbow plot showing percent differences in deuterium exchange between PTPN22 1-330 WT and S325E. Deuterium exchange was assessed for five different time points from 10 to 100000 s. The numbering of the polypeptide chain follows the sequence of the protein as used in the experiment, which has a 17-amino acid N-terminal leader preceding the native methionine 1. Data are representative of two independent experiments. B , the averages of number of deuterium exchanged (#D) shown over time for two of the peptides with the greatest changes. C , ribbon representation of PTPN22 (PDB code 2P6X ) annotated with the location of the active site and of polypeptide regions mentioned in the text. For reference, the ribbon color matches the bottom band in the sequence view in A. D , solvent accessible surface representation of the PTP domain in two orthogonal views colored according to the percent difference in the exchange rate at 10,000 s as shown in A. Key residues are indicated. The molecular graphics objects in ( C ) and ( D ) were generated with UCSF Chimera . Ni-NTA, nickel-nitrilotriacetic acid; PTP, protein tyrosine phosphatase; PTPN22, PTP nonreceptor type 22.

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: Effect of Ser 325 phosphorylation mimic on the deuterium exchange rates of PTPN22 1 to 330. A , rainbow plot showing percent differences in deuterium exchange between PTPN22 1-330 WT and S325E. Deuterium exchange was assessed for five different time points from 10 to 100000 s. The numbering of the polypeptide chain follows the sequence of the protein as used in the experiment, which has a 17-amino acid N-terminal leader preceding the native methionine 1. Data are representative of two independent experiments. B , the averages of number of deuterium exchanged (#D) shown over time for two of the peptides with the greatest changes. C , ribbon representation of PTPN22 (PDB code 2P6X ) annotated with the location of the active site and of polypeptide regions mentioned in the text. For reference, the ribbon color matches the bottom band in the sequence view in A. D , solvent accessible surface representation of the PTP domain in two orthogonal views colored according to the percent difference in the exchange rate at 10,000 s as shown in A. Key residues are indicated. The molecular graphics objects in ( C ) and ( D ) were generated with UCSF Chimera . Ni-NTA, nickel-nitrilotriacetic acid; PTP, protein tyrosine phosphatase; PTPN22, PTP nonreceptor type 22.

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: Sequencing, Solvent, Generated

    Effect of mimicking Ser 325 phosphorylation on the interaction between the PTPN22 interdomain and catalytic domain. A , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 interdomain (residues 299–360, black ) and S325E ( blue ). S325 and E325 residues are annotated. B , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 interdomain (residues 299–360) alone ( black ) and in complex with the PTPN22 catalytic domain (residues 1–299; red ). Peaks with changing intensities are annotated. C , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 S325E interdomain (residues 299–360) alone ( blue ) and in complex with the PTPN22 catalytic domain (residues 1–299; red ). Peaks with changing intensities are annotated. HSQC, heteronuclear single quantum coherence; PTPN22, protein tyrosine phosphatase nonreceptor type 22.

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: Effect of mimicking Ser 325 phosphorylation on the interaction between the PTPN22 interdomain and catalytic domain. A , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 interdomain (residues 299–360, black ) and S325E ( blue ). S325 and E325 residues are annotated. B , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 interdomain (residues 299–360) alone ( black ) and in complex with the PTPN22 catalytic domain (residues 1–299; red ). Peaks with changing intensities are annotated. C , 2D [ 1 H, 15 N] HSQC spectrum of 15 N-labeled PTPN22 S325E interdomain (residues 299–360) alone ( blue ) and in complex with the PTPN22 catalytic domain (residues 1–299; red ). Peaks with changing intensities are annotated. HSQC, heteronuclear single quantum coherence; PTPN22, protein tyrosine phosphatase nonreceptor type 22.

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: Labeling

    Primers used in the study

    Journal: The Journal of Biological Chemistry

    Article Title: A novel gain-of-function phosphorylation site modulates PTPN22 inhibition of TCR signaling

    doi: 10.1016/j.jbc.2024.107393

    Figure Lengend Snippet: Primers used in the study

    Article Snippet: Goat anti-human PTPN22 polyclonal antibody was purchased from R&D systems.

    Techniques: Sequencing

    Figure 1. The Src homology 3 (SH3) domain of UBASH3A interacts with PTPN22 in Jurkat cells. (a) Lysates from Jurkat cells and GM12155 cells were immunoprecipitated with anti-UBASH3A or IgG. The immunoprecipitates and the input lysates were subjected to immunoblotting with anti-PTPN22, and subsequently, with anti-UBASH3A after stripping. The asterisk indicates the monoubiquitinated form of UBASH3A. The vertical white line indicates that the lanes are not consecutive, although they are of the same gel. Note that the 91 kDa band observed in lane 4 (upper panel) is likely a false positive result because UBASH3A is not detected in GM12155 cells (bottom panel). (b) Glutathione S-transferase (GST) pull-down assay using GST or GST-tagged ubiquitin-associated (UBA), SH3, and phosphoglycerate mutase-like (PGM) domains of UBASH3A with lysate from Jurkat cells. The pull-down products and the Jurkat lysate were subjected to immunoblotting with anti-PTPN22.

    Journal: International journal of molecular sciences

    Article Title: UBASH3A Interacts with PTPN22 to Regulate IL2 Expression and Risk for Type 1 Diabetes.

    doi: 10.3390/ijms24108671

    Figure Lengend Snippet: Figure 1. The Src homology 3 (SH3) domain of UBASH3A interacts with PTPN22 in Jurkat cells. (a) Lysates from Jurkat cells and GM12155 cells were immunoprecipitated with anti-UBASH3A or IgG. The immunoprecipitates and the input lysates were subjected to immunoblotting with anti-PTPN22, and subsequently, with anti-UBASH3A after stripping. The asterisk indicates the monoubiquitinated form of UBASH3A. The vertical white line indicates that the lanes are not consecutive, although they are of the same gel. Note that the 91 kDa band observed in lane 4 (upper panel) is likely a false positive result because UBASH3A is not detected in GM12155 cells (bottom panel). (b) Glutathione S-transferase (GST) pull-down assay using GST or GST-tagged ubiquitin-associated (UBA), SH3, and phosphoglycerate mutase-like (PGM) domains of UBASH3A with lysate from Jurkat cells. The pull-down products and the Jurkat lysate were subjected to immunoblotting with anti-PTPN22.

    Article Snippet: The following antibodies were used: mouse anti-FLAG (F1804-1MG, MilliporeSigma, Saint Louis, MO, USA), mouse anti-γ-tubulin (T6557, MilliporeSigma, Saint Louis, MO, USA), goat anti-human PTPN22 (AF3428, R&D Systems, Minneapolis, MN, USA), rabbit anti-human UBASH3A (SAB1410972-100UG, MilliporeSigma, Saint Louis, MO, USA; 15823-1-AP, Proteintech Group, Rosemont, IL, USA), and mouse anti-V5 (R960-25, Thermo Fisher Scientific, Lafayette, CO, USA).

    Techniques: Immunoprecipitation, Western Blot, Stripping Membranes, Pull Down Assay, Ubiquitin Proteomics

    Figure 2. Effects of the UBASH3A W279A mutation (in the SH3 domain) and the single-nucleotide polymorphism (SNP) rs2476601 (in PTPN22) on the interaction between UBASH3A and PTPN22. HEK293T cells were co-transfected with constructs encoding the indicated form of FLAG-tagged PTPN22 (wild-type [WT] or R620W [the missense change caused by the minor, risk allele at rs2476601]) and the indicated form of V5-tagged UBASH3A (wild-type [WT] or W279A [SH3 mutant]) or V5. Lysates from the transfected cells were immunoprecipitated with anti-V5. The immunoprecipitates were subjected to immunoblotting with anti-FLAG. The same lysates were subjected to immunoblot- ting with anti-FLAG, and subsequently, with anti-V5 and anti-γ-tubulin after stripping. The arrow indicates FLAG-tagged wild-type or R620W PTPN22. The arrowhead indicates V5-tagged UBASH3A. The asterisk indicates the monoubiquitinated form of V5-tagged UBASH3A.

    Journal: International journal of molecular sciences

    Article Title: UBASH3A Interacts with PTPN22 to Regulate IL2 Expression and Risk for Type 1 Diabetes.

    doi: 10.3390/ijms24108671

    Figure Lengend Snippet: Figure 2. Effects of the UBASH3A W279A mutation (in the SH3 domain) and the single-nucleotide polymorphism (SNP) rs2476601 (in PTPN22) on the interaction between UBASH3A and PTPN22. HEK293T cells were co-transfected with constructs encoding the indicated form of FLAG-tagged PTPN22 (wild-type [WT] or R620W [the missense change caused by the minor, risk allele at rs2476601]) and the indicated form of V5-tagged UBASH3A (wild-type [WT] or W279A [SH3 mutant]) or V5. Lysates from the transfected cells were immunoprecipitated with anti-V5. The immunoprecipitates were subjected to immunoblotting with anti-FLAG. The same lysates were subjected to immunoblot- ting with anti-FLAG, and subsequently, with anti-V5 and anti-γ-tubulin after stripping. The arrow indicates FLAG-tagged wild-type or R620W PTPN22. The arrowhead indicates V5-tagged UBASH3A. The asterisk indicates the monoubiquitinated form of V5-tagged UBASH3A.

    Article Snippet: The following antibodies were used: mouse anti-FLAG (F1804-1MG, MilliporeSigma, Saint Louis, MO, USA), mouse anti-γ-tubulin (T6557, MilliporeSigma, Saint Louis, MO, USA), goat anti-human PTPN22 (AF3428, R&D Systems, Minneapolis, MN, USA), rabbit anti-human UBASH3A (SAB1410972-100UG, MilliporeSigma, Saint Louis, MO, USA; 15823-1-AP, Proteintech Group, Rosemont, IL, USA), and mouse anti-V5 (R960-25, Thermo Fisher Scientific, Lafayette, CO, USA).

    Techniques: Mutagenesis, Transfection, Construct, Immunoprecipitation, Western Blot, Stripping Membranes

    H21I substitution in the SH3 domain of Csk selectively disrupts self-association. ( a ) Position of the SH3 domain in full-length Csk (PDB ID: 1K9A ). ( b ) Csk residue H21 in the SH3/SH3 homodimer interface (PDB ID 1CSK ). The position of PTPN22 peptide binding to the SH3 domain was derived in PyMol using PDB IDs 1K9A 1CSK , 1JEG , 1QWE , and 2P6X . ( c ) Representative immunoblots of whole-cell or Myc-immunodepleted lysates from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both H21I). ( d ) Corresponding immunoblots of transfected Csk and endogenous PTPN22 in Myc immunoprecipitates. ( e ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: standard error of the mean (SEM), n = 4 independent experiments. Significance: one-way ANOVA with Tukey’s multiple comparison test (Sig.ANOVA) ****p < 0.0001, ***p = 0.0001 or 0.0008.

    Journal: Scientific Reports

    Article Title: SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding

    doi: 10.1038/s41598-022-09589-9

    Figure Lengend Snippet: H21I substitution in the SH3 domain of Csk selectively disrupts self-association. ( a ) Position of the SH3 domain in full-length Csk (PDB ID: 1K9A ). ( b ) Csk residue H21 in the SH3/SH3 homodimer interface (PDB ID 1CSK ). The position of PTPN22 peptide binding to the SH3 domain was derived in PyMol using PDB IDs 1K9A 1CSK , 1JEG , 1QWE , and 2P6X . ( c ) Representative immunoblots of whole-cell or Myc-immunodepleted lysates from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both H21I). ( d ) Corresponding immunoblots of transfected Csk and endogenous PTPN22 in Myc immunoprecipitates. ( e ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: standard error of the mean (SEM), n = 4 independent experiments. Significance: one-way ANOVA with Tukey’s multiple comparison test (Sig.ANOVA) ****p < 0.0001, ***p = 0.0001 or 0.0008.

    Article Snippet: Membranes were blocked with 3% bovine serum albumin (Sigma), and then incubated with the primary antibodies goat anti-human PTPN22/Lyp (AF3428, R&D Biosciences), anti-Myc Biotinylated antibody (71D10, Cell Signaling Tech #3946), or anti-HA Biotinylated antibody (C29F4, Cell Signaling Tech #5017).

    Techniques: Binding Assay, Derivative Assay, Western Blot, Transfection, Construct

    Unlike W47A, K43D substitution in the SH3 domain of Csk selectively disrupts PTPN22 binding. ( a ) Csk residue K43D in the secondary binding interface between PTPN22 and the SH3 domain of Csk. The binding site for the proline (P) residues in the peptide PXXP motif, including Csk W47A, overlap with the dimer footprint; only one of the proline residues is engaged in this structure. ( b ) Representative immunoprecipitate blots from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both K43D). ( c ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: SEM, n = 3. Sig.ANOVA *p = 0.0133 or 0.0451. ( d ) Representative immunoprecipitate blots from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both W47A). Boxed images cropped from non-adjacent lanes of the same blot with brightness/contrast corrections applied uniformly prior to cropping. ( e ) Quantifications from immunoprecipitate blots, corrected as above. Error bars: SEM, n = 4. Sig.ANOVA **p = 0.0010, *p = 0.0282.

    Journal: Scientific Reports

    Article Title: SH3-domain mutations selectively disrupt Csk homodimerization or PTPN22 binding

    doi: 10.1038/s41598-022-09589-9

    Figure Lengend Snippet: Unlike W47A, K43D substitution in the SH3 domain of Csk selectively disrupts PTPN22 binding. ( a ) Csk residue K43D in the secondary binding interface between PTPN22 and the SH3 domain of Csk. The binding site for the proline (P) residues in the peptide PXXP motif, including Csk W47A, overlap with the dimer footprint; only one of the proline residues is engaged in this structure. ( b ) Representative immunoprecipitate blots from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both K43D). ( c ) Quantifications from immunoprecipitate blots, corrected for Csk Myc pulldown in each sample, shown relative to WT. Error bars: SEM, n = 3. Sig.ANOVA *p = 0.0133 or 0.0451. ( d ) Representative immunoprecipitate blots from Jurkat cells transfected with Csk HA and Csk Myc constructs (both WT or both W47A). Boxed images cropped from non-adjacent lanes of the same blot with brightness/contrast corrections applied uniformly prior to cropping. ( e ) Quantifications from immunoprecipitate blots, corrected as above. Error bars: SEM, n = 4. Sig.ANOVA **p = 0.0010, *p = 0.0282.

    Article Snippet: Membranes were blocked with 3% bovine serum albumin (Sigma), and then incubated with the primary antibodies goat anti-human PTPN22/Lyp (AF3428, R&D Biosciences), anti-Myc Biotinylated antibody (71D10, Cell Signaling Tech #3946), or anti-HA Biotinylated antibody (C29F4, Cell Signaling Tech #5017).

    Techniques: Binding Assay, Transfection, Construct